1. World Health Organization. Preventing and Managing the Global Epidemic of obesity. Geneva, 3-5 June 1997. http://www.who.int/nutrition/publications/obesity_executive_summary.pdf
2. Bray G., Bouchard C., James WPT. Definitions and proposed current classifications of obesity. En: Bray, G., Bouchard, C., James WPT, Editores. Handbook of obesity, Nova York: Marcek Dekker, 1998; 31-40.
3. Consenso SEEDO’2000 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Med Clin (Barc) 2000; 115: 587-597. http://www.seedo.es/Publicaciones/consenso2K.htm
4. Report of a WHO Consultation on Obesity, Geneva 3-5 June 1997. Obesity: preventing and managing the Global Epidemic. WHO publications: Geneva, 1997.
5. Kuczmarski, RJ., Flegal KM., Campbell, JM., Jphnson, CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960-1991. JAMA 1994; 272: 205-211.
6. Aranceta, J, Pérez Rodrigo, C., Serra, Ll., Ribas, L., Quiles, J., Vioque, J. et al. y grupo colaborativo español para el estudio de la obesidad. Prevalencia de la obesidad en España: estudio de la SEEDO. Med Clin (Barc) 1998; 11: 441-445. http://www.seedo.es/publicaciones/ConsensoSEEDO2003.pdf
7. Sáez M., Garcia-Rafanell, JM., Fernández-Real, JM., Barceló, MA., Saurina, C., et al. Prevalencia de la obesidad en la población atendida en Asistencia Primaria de Girona, 1995-1999. Gac Sanit 2001; 15(2):1-10.
8. Mc Ginnius JM., Foege, WH. Actual causes of death in US: JAMA 1993; 270: 2207-2212.
9. Kvist H., Chowdhury B., Grangard, U. et al. Total and visceral adipose tissue volumes derived from measurements with computed tomography in adult men and women. Predictive equations. American Journal of Clinical Endocrinology and Metabolism 1988, 48: 1351-1361.
10. Van Gaal, LF., Wauters, MA., De Leeuw, IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes 21 (suppl) 1997: 397-415.
11. Coronas, R., Forga, M., Leyes, P. Dietas de muy bajo contenido calórico (VLDL). Nutrición y obesidad 2000; 3: 300-305.
12. Pronk, N. & Wing, R. Physical activity and long-term maintenance of weight loss. Obesity Research 1994;2: 587-599.
13. Ewbank, PP., Darga, Ll. & Lucas, CP. Physical activity as a predictor of weight maintenance in previously obese subjects. Obesity Research 1995; 3: 257-264.
14. Bray, GA. (1998). Contemporary diagnosis and the management of obesity. Newton, PA, USA: Handbooks in Health Care.
15. Toubro S., Astrup A., Breum, L. & Quaade, F. The acute and chronic effects of ephedrine /caffeine mixtures on energy and glucose metabolism in humans. International Journal of Obesity and Related Metabolic Disorders 1993; 17 (suplement 3): 573-577.
16. Rössner, S., Sjöstrom, L., Noack, R., Weight, L. Weight Maintenance and Improved Cardiovascular Risk factors after 2 years treatment with Orlistat for Obesity. Obesity Research 2000; 8: 49-61.
17. Kaplan, N. Obesity in hypertension: effects on prognosis and treatment. Journal of Hypertension. 1998;16 (1) supplement; 35-37.
18. Benotti, P., Bistrian, B., Benotti, J. et al. Heart disease and hypertension in severe obesity: the benefits of weight reduction. American Journal of Clinical Nutrition 1992; 55 (supplement): 5865-5905.
19. Letiexhe MR., Scheen AJ., Gerard PL. et al. Postgastroplasty recovery of ideal body weight normalizes glucose and insulin metabolism in obese women. Journal of Clinical Endocrinology and Metabolism, 1995;80: 264-269.
20. Bouchard, D. Obesity in adulthood-The importance of childhood and parental obesity. N. Engl, J. Med,1997; 337: 926-7.
21. Long, S., O’Brien, K., MacDonald KG, JR. et al. Weight loss in severely obese subjects prevents progression of impaired glucose tolerance to type II diabetes. Diabetes Care 1997; 17: 372-375.
22. Alastrue, A., Rull, M., Formiguera, X., Casas, D., Moreno, P., Mira, X., Cudis-Casas, G., Foz, M., Broggi, MA. Cirugía de la obesidad grave. Endocrinología y nutrición, 1999 45, 1: 22-42.
23. Anonymous. Gastrointestinal surgery for severe obesity. National Institutes of Health Consensus Development Conference Statement. American Journal of Clinical Nutrition 1992; 55 (supplement 2): 6155-6195. http://www.ajcn.org/cgi/reprint/55/2/615S
24. Heymsfield, S., Karen, R., Hauptman, J., Lucas, C., Boldrim, M., Rissanen, A., Wilding, J., Sjöstrom, L. Effects of Weight Loss With Orlistat on Glucose Tolerance and Progression to Type 2 Diabetes and Obese Adults. Arch Intern Med, 2000; 160: 1321-1326.
25. Hollander, P., Elbein, S., Hirsch, I., Kelley, D., McGill, J. et al. Role of Orlsitat in the Treatment of Obese Patients With Type 2 Diabetes. Diabetes Care, 1998; 21: 1288-1294.
26. Wing, R., Blair, E., Bonori, P., Marcus, M., Watanabe, R., Bergman, R. Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM. Diabetes Care 1994; 17: 30-36.
27. Karhunen, L., Franssila-Kallunki, A., Rissanen, P., Valve, R., Kolehmanien, M. et al. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. International Journal of Obesity, 2000: 24; 1567-1572. http://www.bmj.com/cgi/content/full/311/6998/158
28. UK Prospective Diabetes Study Group. Effect if inverse blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998: 352; 854-65.
29. Shapira, NA., Goldsmith, TD., McElroy, SL. Treatment of binge-eating disorder with topiramate: a clinical series. J Clin Psychiatry, 2000; 61 (5): 368-372.
30. Lean, ME., Han, TS., Morrison, CE. Waist circumference as a mesure for indicating need for weight management. Br Med, J., 1995; 311: 158-161.
31. Dixon, JB., Schachter, LM., O'Brien, PE. Sleep Disturbance and Obesity. Ann Intern Med, 2001; 161: 102-106.
32. UK Prospective Study (UKPDS) Group. Intensive blood-glucose control with sulphonilureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352: 837-853.
33. Pontiroli, AE., Pacchioni, M., Piatti, PM., Cassisa, C., Camisasca, P., Pozza, G. Benfluorex in obese non insulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. J Clin Endocrinol Metab., 1996; 81: 3727-32.
34. Stevens, J., Ci, J., Pamuk, E. The effect of age on the association between body-mass index and mortality. N Engl J Med.,1998: 338: 1-7.
35. Yki-Järvinen, H., Ryysy, L., Nikkilä, K., Tulokas, T. et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann Intern Med 1999: 130: 389-396.
36. Executive Summary of the Third Report Of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285, 19: 2486-2508.
37. Dixon, JB., Shachter, LM., O’Brien, PE. Sleep disturbance and obesity. Arch Intern Med 2001: 161; 102-106.
38. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEJM, 2002; 346 (6): 393-403.
39. Kolotkin, RL., Crosby, RD., Koloski, KD., Williams, GR. Development of a brief measure to assess quality of life in obesity. Obesity Research, 2002, 9, 102-111.
40. Etotté E., Hendrixks L., Pauwels M., Van hee R. Weight Reduction by Means of Intragastric Device. Experience with Bioenterics Intragastric Ballon. Obes Sug. 2003; 11: 519-523
41. SEMFYC. Manejo de las dislipemias en Atención primaria. 1997.
42. A. Martin Zurro y Cano Pérez. Compendio de Atención Primaria. Obesidad. 304-315; 1999
43. Expert Panel on the Identification, Evaluation and Treatment of Overweight in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Am J Clin Nutr, 1998;68:899-917. http://www.ajcn.org/cgi/reprint/68/4/899.pdf
44. WHO. Technical Report series, 894. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation on Obesity. World Health Organization. Ginebra 1999.
45. Grupo de Trabajo sobre Riesgo Cardiovascular de la gerencia de Atención Primaria de Valladolid Oeste. Guía Clínica del manejo de la Obesidad. http://www.fisterra.com/guías2/obesidad.htm
46. An Evidence-Based Assessment of Federal Guidelines for Overweight and Obesity as They Apply to Elderly Persons. Arch Inter Med 2001; 161(9). http://archinte.amaassn.org/issues/v161n9/abs/ioi00523.html
47. US Department of Health and Human Services. The Surgeon General’s call to action to prevent and decrease overweight and obesity. Rockville US Department of Health and Human Services, Public Health Service, Office of the Surgeon General, 2001 Washington: USA Government Printing Office. http://www.surgeongeneral.gov/topics/obesity/calltoaction/CalltoAction.pdf
48. Korner J., Aronne L.J. Pharmacological Approaches to Weight Reduction: Therapeutic Targets. JCEM 2004; 89: 2616-2621.
49. Arrizabalaga J.J., Masmiquel L., Vidal J., Calañas-Continente A. Díaz Fernández M.J. et al. Conferencia de Consenso. Recomendaciones y algoritmo de tratamiento del sobrepeso y la obesidad en personas adultas. Med. Clin (Barc) 2004; 122: 104-110.
50. Rubui MA., Moderon C. Dietas de muy bajo contenido calórico: adaptación a nuevas recomendaciones. Rev. Esp. Obes. 2004; 2: 91-98.
51. Guía práctica clínica para el manejo del sobrepeso y la obesidad en personas adultas. Endocrinología y Nutrición 2003: 50; supl 4.
52. Bray G. Medical Consequences of Obesity. JCEM 2004: 89: 2583-89. http://jcem.endojournals.org/cgi/content/full/89/6/2583
53. Buchwald H. Bariatric Surgery A systematic review and meta-analysis. JAMA October 13, 2004- vol 292/14.
54. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care 2005 28: S4-3. http://care.diabetesjournals.org/cgi/content/full/29/suppl_1/s4
55. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283:1967–1975. RT 18
56. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997. RT http://www.infodoctor.org/rafabravo/allhat.html
57. A. Coca; A. De la Sierra. Decisiones clínicas y terapéuticas en el paciente Hipertenso. Editorial JIMS; BCN 2002
58. José López-Sendón, Karl Swedberg, John McMurray, Juan Tamargo, Aldo P. Maggioni, Henry Dargie, Michal Tendera, Finn Waagstein, Jan Kjekshus, Philippe Lechatj y Christian Torp-Pedersen (Grupo de Trabajo sobre inhibidores de la enzima de conversión de la angiotensina). Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversión de la angiotensina en la enfermedad cardiovascular.
59. Giovanni F M Strippoli, Maria Craig, Jonathan J Deeks, Francesco Paolo Schena, and Jonathan C Craig. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828, doi:10.1136/bmj.38237.585000.7C
60. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751–1756. RT
61. Dahlo¨ f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995–1003. RT
62. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713–720. RT
63. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611–616. RT
64. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) Trial of Cardiovascular Events in Hypertension. Rationale and Design Mann J, Julius S, For the VALUE Trial Group. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure 1998; 7: 176–183.
65. Heymsfield SB, Van Mierlo CAJ, Van der Knaap HCM, Heo M, Frier HI. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes 2003; 27: 537-49.
66. Rössner S. Intermitent vs. continuous VLCD therapy in obesity treatment. Int J Obes 1999; 23: 190-7.
67. Devlin, M.J., Goldfein, J.A. i Dobrow I. What is this thing called BED?, Current status of binge eating disorder nosology. International Journal of Eating Disorders. 2003. 34, S2-S18.
68. Henderson M., Freeman PL. A self-rating Scale for Bulimia. The BITE. Br. J. Psychiatry 1987; 150: 18-24.
69. National Institutes of Health. National Hearth, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The evidence report. Bethesda: National Heart, Lung, and Blood Institute, 1998;p 1-228. A http://www.nhlbi.nih.gov/guidelines/obesity/ob_home.htm
70. SIGN. Obesity in Scotland: Integrating prevention with weight management. A National Clinical Guideline. Edingburg: Scottish Intercollegiate Guidelines Network, 1996; p 1-71. http://www.sign.ac.uk/guidelines/published/index.html.
71. Scottish Intercollegiate Guidelines Network. SIGN 50: a guideline developers’ handbook. Edinburgh: SIGN, 2001. http://www.sign.ac.uk/guidelines/fulltext/50/index.html
72. Scottish Intercollegiate Guidelines Network. Management of diabetes. http://www.sign.ac.uk/pdf/qrg55.pdf
73. National Institute for Health and Clinical Excellence. Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. December 2006. http://www.nice.org.uk/guidance/CG43/guidance/section5b/word/English
73. American Diabetes Association. Evidence-Based Nutrition Principles and Recommendations for the Treatment and Prevention of Diabetes and Related Complications. Diabetes Care 25:S50-S60, 2002. http://care.diabetesjournals.org/cgi/content/full/25/suppl_1/s50#SEC10
75. MedlinePlus. Ma huang. http://www.nlm.nih.gov/medlineplus/spanish/druginfo/natural/patient-ephedra.html
76. MedlinePlus. Psyllium. http://www.nlm.nih.gov/medlineplus/print/druginfo/natural/patient-psyllium.html
77. Padwal R, Li SK, Lau DW. Tratamiento farmacológico a largo plazo para la obesidad y el sobrepeso (revisión Cochrane traducida). Biblioteca Cochrane Plus 2006, nº 4. Oxford: Update Software ltd. http://www.update-software.com
78. Rico Iturrioz RM. Tratamiento quirúrgico de la obesidad. Servicios de evaluación de tecnologías sanitaria. Osteba. Departamento de sanidad. Dirección de planificación y ordenación sanitaria del gobierno vasco. Vitoria-Gasteiz 2003. http://euskadi.net/sanidad/osteba
79 Cano-Pérez J, Franch J, Mata M. Guía de tratamiento de la diabetes tipo 2 en Atención Primaria. GedapS. Elsevier. 07-2004.
80. Departament de Salut de Girona. CatSalut. Protocol d'atenció integral i específic en TCA de la Regió Sanitària Girona. Maig 2006. http//:www10.gencat.net/catsalut/cat/girona_publica.htm.
81. Somerset and Wessex Eating Disorders Association: Eating Disorders: Definitions & Diagnosis. 2004-2007. http://www.swedauk.org/disorders/definitions.htm.
82. C. Fontealba. Trastornos de la conducta alimentaria y obesidad. http://www.med.uchile.cl/apuntes/archivos/2006/medicina/tca_y_obesidad_5.pdf.
83. M Tortella. Apunts de Teràpia de Conducta. Trastorns alimentaris. www.uib.es/facultat/psicologia/docencia/tortella/tema12ALIMENTA.pdf.
84. Javier Aranceta. Obesidad infantil y factores determinantes. Estudio enKid (1998-200). http://www.seedo.es/portals/seedo/consenso/Prevalencia_ni%C3%B1os_Estudio_ENKID(Med_Clin_2003).pdf.
85. Instituto de Investigación sobre Crecimiento y Desarrollo. Fundación Faustino Orbegozo. Curvas y Tablas de Crecimiento. Bilbao: http://www.aepap.org/pdf/f_orbegozo_04.pdf.
(en construcción)
Puede descargar el programa informático (CalcObes) con todo lo que lleva en http://sourceforge.net/projects/calcobes
Sílvia Mauri y Anna Pibernat: endocrino@htrueta.scs.es
Emili Mas: emas@hosppal.es
Concepció de Ribot: cderibot@hosppal.es
David Pérez: dpereza@hosppal.es
Dídac Ettinghausen: dettinghausen@hosppal.es
Jordi March: jmarch@hosppal.es
Esta Guía se referenciará como:
GirObSMet. Guía Clínica de Actuación en la Obesidad. Girona 2007.
Esta Guía se rige por una licencia de
Atribución-NoComercial-CompartirDerivadasIgual 2.5 España
| Usted es libre de: | |
 |
Copiar, distribuir y exhibir la obra. |
 |
Hacer obras derivadas. |
| Bajo las siguientes condiciones: | |
 |
Atribución. Usted debe atribuir la obra en la forma especificada por el autor o el licenciante. |
 |
No Comercial. Usted no puede usar esta obra con fines comerciales. |
 |
Compartir Obras Derivadas Igual. Si usted altera, transforma, o crea sobre esta obra, sólo podrá distribuir la obra derivada resultante bajo una licencia idéntica a ésta. |
Ante cualquier reutilización o distribución, usted debe dejar claro a los otros los términos de la licencia de esta obra.
Cualquiera de estas condiciones puede dispensarse si usted obtiene permiso del titular de los derechos de autor.
Sus usos legítimos u otros derechos no son afectados de ninguna manera por lo dispuesto precedentemente.
Este es un resumen fácilmente legible del Código Legal (la licencia completa) que usted puede encontrar en:http://creativecommons.org/licenses/by-nc-sa/2.5/es/legalcode.es